Information Provided By: 
Fly News Breaks for March 20, 2019
SPHS
Mar 20, 2019 | 10:00 EDT
JonesTrading analyst Matthew Cross downgraded Sophiris Bio to Hold from Buy to reflect the increased risk he sees as the company attempts to secure funding for continued clinical development of topsalysin in prostate cancer. While he continues to view topsalysin as a highly attractive asset, the end of Sophiris' cash runway is "fast approaching," Cross tells investors.
News For SPHS From the Last 2 Days
There are no results for your query SPHS
